{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:53:32Z","timestamp":1787306012599,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["249032\/2013-9"],"award-info":[{"award-number":["249032\/2013-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12035-018-1426-9","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T14:01:55Z","timestamp":1542808915000},"page":"5067-5074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls"],"prefix":"10.1007","volume":"56","author":[{"given":"Tain\u00e1 M.","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouke","family":"van Rumund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona B.","family":"Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J. C. T.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolein","family":"Gloerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne A. J.","family":"Esselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bea","family":"Kuiperij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-7876","authenticated-orcid":false,"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"issue":"9996","key":"1426_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1426_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe W (2008) Non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 15(Suppl 1):14\u201320. \nhttps:\/\/doi.org\/10.1111\/j.1468-1331.2008.02056.x","journal-title":"Eur J Neurol"},{"issue":"6","key":"1426_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/s1474-4422(16)00116-2","volume":"15","author":"RB Postuma","year":"2016","unstructured":"Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG et al (2016) The new definition and diagnostic criteria of Parkinson\u2019s disease. Lancet Neurol 15(6):546\u2013548. \nhttps:\/\/doi.org\/10.1016\/s1474-4422(16)00116-2","journal-title":"Lancet Neurol"},{"issue":"12","key":"1426_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. \nhttps:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"issue":"10","key":"1426_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/jnnp-2013-307539","volume":"85","author":"N Magdalinou","year":"2014","unstructured":"Magdalinou N, Lees AJ, Zetterberg H (2014) Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 85(10):1065\u20131075. \nhttps:\/\/doi.org\/10.1136\/jnnp-2013-307539","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1426_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/bmm.14.105","volume":"10","author":"AH Simonsen","year":"2016","unstructured":"Simonsen AH, Kuiperij B, El-Agnaf OM, Engelborghs S, Herukka SK, Parnetti L, Rektorova I, Vanmechelen E et al (2016) The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med 10(1):19\u201334. \nhttps:\/\/doi.org\/10.2217\/bmm.14.105","journal-title":"Biomark Med"},{"issue":"2","key":"1426_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00415-014-7568-4","volume":"262","author":"MB Aerts","year":"2015","unstructured":"Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, Janssen MJ, Borm GF et al (2015) Ancillary investigations to diagnose parkinsonism: a prospective clinical study. J Neurol 262(2):346\u2013356. \nhttps:\/\/doi.org\/10.1007\/s00415-014-7568-4","journal-title":"J Neurol"},{"issue":"3","key":"1426_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1426_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670\u2013676. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15","journal-title":"Neurology"},{"issue":"1","key":"1426_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1\u20139","journal-title":"Neurology"},{"issue":"6","key":"1426_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"G\u00fcnter U. H\u00f6glinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Muller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Movement Disorder Society-endorsed PSPSG (2017) Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 32 (6):853\u2013864. doi:\nhttps:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Movement Disorders"},{"issue":"10 Suppl 3","key":"1426_CR12","first-page":"S11","volume":"57","author":"MM Hoehn","year":"2001","unstructured":"Hoehn MM, Yahr MD (2001) Parkinsonism: onset, progression, and mortality. 1967. Neurology 57(10 Suppl 3):S11\u2013S26","journal-title":"Neurology"},{"issue":"7","key":"1426_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s D","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s D (2003) The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738\u2013750. \nhttps:\/\/doi.org\/10.1002\/mds.10473","journal-title":"Mov Disord"},{"issue":"2","key":"1426_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","volume":"145","author":"P Trouillas","year":"1997","unstructured":"Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC et al (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145(2):205\u2013211","journal-title":"J Neurol Sci"},{"issue":"7","key":"1426_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/archpsyc.1983.01790060110016","volume":"40","author":"MF Folstein","year":"1983","unstructured":"Folstein MF, Robins LN, Helzer JE (1983) The mini-mental state examination. Arch Gen Psychiatry 40(7):812","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1426_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","volume":"20","author":"MK Herbert","year":"2014","unstructured":"Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, Kuiperij HB, Verbeek MM (2014) CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 20(1):112\u2013115. \nhttps:\/\/doi.org\/10.1016\/j.parkreldis.2013.09.003","journal-title":"Parkinsonism Relat Disord"},{"key":"1426_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00091","volume":"6","author":"MK Herbert","year":"2015","unstructured":"Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RA, Bloem BR, Kuiperij HB, Verbeek MM (2015) CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol 6:91. \nhttps:\/\/doi.org\/10.3389\/fneur.2015.00091","journal-title":"Front Neurol"},{"issue":"2","key":"1426_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.neurobiolaging.2010.12.001","volume":"33","author":"MB Aerts","year":"2012","unstructured":"Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33(2):430\u2013e431-433. \nhttps:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.12.001","journal-title":"Neurobiol Aging"},{"issue":"12","key":"1426_CR19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26(12):1367\u20131372. \nhttps:\/\/doi.org\/10.1038\/nbt.1511","journal-title":"Nat Biotechnol"},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S et al (2015) A practical guide to immunoassay method validation. Front Neurol 6:179. \nhttps:\/\/doi.org\/10.3389\/fneur.2015.00179","journal-title":"Front Neurol"},{"issue":"1","key":"1426_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/jnc.13527","volume":"137","author":"LJ Waalwijk van Doorn van","year":"2016","unstructured":"van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Haussmann U, Klafki H, Struyfs H, Linning P, Knolker HJ, Twaalfhoven H et al (2016) Validation of soluble amyloid-beta precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. J Neurochem 137(1):112\u2013121. \nhttps:\/\/doi.org\/10.1111\/jnc.13527","journal-title":"J Neurochem"},{"issue":"11","key":"1426_CR22","doi-asserted-by":"publisher","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","volume":"16","author":"I Camby","year":"2006","unstructured":"Camby I, Le Mercier M, Lefranc F, Kiss R (2006) Galectin-1: a small protein with major functions. Glycobiology 16(11):137R\u2013157R. \nhttps:\/\/doi.org\/10.1093\/glycob\/cwl025","journal-title":"Glycobiology"},{"issue":"7","key":"1426_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1023\/b:glyc.0000014077.84016.52","volume":"19","author":"H Horie","year":"2002","unstructured":"Horie H, Kadoya T (2002) Galectin-1 plays essential roles in adult mammalian nervous tissues. Roles of oxidized galectin-1. Glycoconj J 19(7):479\u2013489. \nhttps:\/\/doi.org\/10.1023\/b:glyc.0000014077.84016.52","journal-title":"Glycoconj J"},{"issue":"6","key":"1426_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2990.2011.01184.x","volume":"37","author":"M Stancic","year":"2011","unstructured":"Stancic M, van Horssen J, Thijssen VL, Gabius HJ, van der Valk P, Hoekstra D, Baron W (2011) Increased expression of distinct galectins in multiple sclerosis lesions. Neuropathol Appl Neurobiol 37(6):654\u2013671. \nhttps:\/\/doi.org\/10.1111\/j.1365-2990.2011.01184.x","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"10","key":"1426_CR25","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1007\/s00018-007-6476-5","volume":"64","author":"M Sakaguchi","year":"2007","unstructured":"Sakaguchi M, Imaizumi Y, Okano H (2007) Expression and function of galectin-1 in adult neural stem cells. Cell Mol Life Sci 64(10):1254\u20131258. \nhttps:\/\/doi.org\/10.1007\/s00018-007-6476-5","journal-title":"Cell Mol Life Sci"},{"key":"1426_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/978-1-4939-1154-7_24","volume":"9","author":"HL Chen","year":"2014","unstructured":"Chen HL, Liao F, Lin TN, Liu FT (2014) Galectins and neuroinflammation. Adv Neurobiol 9:517\u2013542. \nhttps:\/\/doi.org\/10.1007\/978-1-4939-1154-7_24","journal-title":"Adv Neurobiol"},{"issue":"1","key":"1426_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.expneurol.2005.04.004","volume":"195","author":"J McGraw","year":"2005","unstructured":"McGraw J, Gaudet AD, Oschipok LW, Kadoya T, Horie H, Steeves JD, Tetzlaff W, Ramer MS (2005) Regulation of neuronal and glial galectin-1 expression by peripheral and central axotomy of rat primary afferent neurons. Exp Neurol 195(1):103\u2013114. \nhttps:\/\/doi.org\/10.1016\/j.expneurol.2005.04.004","journal-title":"Exp Neurol"},{"issue":"11","key":"1426_CR28","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1111\/j.1460-9568.2004.03802.x","volume":"20","author":"J McGraw","year":"2004","unstructured":"McGraw J, McPhail LT, Oschipok LW, Horie H, Poirier F, Steeves JD, Ramer MS, Tetzlaff W (2004) Galectin-1 in regenerating motoneurons. Eur J Neurosci 20(11):2872\u20132880. \nhttps:\/\/doi.org\/10.1111\/j.1460-9568.2004.03802.x","journal-title":"Eur J Neurosci"},{"issue":"1","key":"1426_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.expneurol.2005.02.011","volume":"194","author":"R Chang-Hong","year":"2005","unstructured":"Chang-Hong R, Wada M, Koyama S, Kimura H, Arawaka S, Kawanami T, Kurita K, Kadoya T et al (2005) Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 194(1):203\u2013211. \nhttps:\/\/doi.org\/10.1016\/j.expneurol.2005.02.011","journal-title":"Exp Neurol"},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.brainres.2007.03.073","volume":"1153","author":"L Zhang","year":"2007","unstructured":"Zhang L, Chang M, Li H, Hou S, Zhang Y, Hu Y, Han W, Hu L (2007) Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res 1153:196\u2013203. \nhttps:\/\/doi.org\/10.1016\/j.brainres.2007.03.073","journal-title":"Brain Res"},{"key":"1426_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1477-5956-6-8","volume":"6","author":"CJ Werner","year":"2008","unstructured":"Werner CJ, Heyny-von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson\u2019s disease. Proteome Sci 6:8. \nhttps:\/\/doi.org\/10.1186\/1477-5956-6-8","journal-title":"Proteome Sci"},{"key":"1426_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/b978-0-12-804279-3.00007-1","volume":"146","author":"TM Marques","year":"2017","unstructured":"Marques TM, Van Rumund A, Kuiperij HB, Verbeek MM (2017) Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. Handbook Clin Neurol 146:99\u2013113. \nhttps:\/\/doi.org\/10.1016\/b978-0-12-804279-3.00007-1","journal-title":"Handbook Clin Neurol"},{"issue":"6","key":"1426_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/cdd.2014.14","volume":"21","author":"HR Quint\u00e1","year":"2014","unstructured":"Quint\u00e1 HR, Pasquini JM, Rabinovich GA, Pasquini LA (2014) Glycan-dependent binding of galectin-1 to neuropilin-1 promotes axonal regeneration after spinal cord injury. Cell Death Differ 21(6):941\u2013955. \nhttps:\/\/doi.org\/10.1038\/cdd.2014.14","journal-title":"Cell Death Differ"},{"issue":"8","key":"1426_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3969\/j.issn.1673-5374.2012.08.010","volume":"7","author":"H Wang","year":"2012","unstructured":"Wang H, Wu M, Zhan C, Ma E, Yang M, Yang X, Li Y (2012) Neurofilament proteins in axonal regeneration and neurodegenerative diseases. Neural Regen Res 7(8):620\u2013626. \nhttps:\/\/doi.org\/10.3969\/j.issn.1673-5374.2012.08.010","journal-title":"Neural Regen Res"},{"issue":"22","key":"1426_CR35","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22):1914\u20131922. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e3181c47cc2","journal-title":"Neurology"},{"key":"1426_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.dadm.2017.03.005","volume":"8","author":"Eline A.J. Willemse","year":"2017","unstructured":"Willemse EAJ, van Uffelen KWJ, van der Flier WM, Teunissen CE (2017) Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A\u03b2(1-42), T-tau, and P-tau values. Alzheimers Dement Diagn Assess Dis Monit 8:45\u201350. \nhttps:\/\/doi.org\/10.1016\/j.dadm.2017.03.005","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1426-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T08:28:49Z","timestamp":1575880129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1426-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,21]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1426-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,21]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent, and the study was approved by the local institutional review board Arnhem-Nijmegen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}